• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13D/A filed by Ontrak Inc.

    6/25/24 7:45:11 PM ET
    $OTRK
    Misc Health and Biotechnology Services
    Health Care
    Get the next $OTRK alert in real time by email
    SC 13D/A 1 tm2418168-1_sc13da.htm SC 13D/A

     

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D. C. 20549

     

    SCHEDULE 13D

     

    Under the Securities Exchange Act of 1934

     

    (Amendment No. 25)*

     

      Ontrak, Inc.   
      (Name of Issuer)  

     

      Common Stock, $0.0001 par value per share  
      (Title of Class of Securities)  

     

      44919F 104  
      (CUSIP Number of Class of Securities)  

     

    Terren S. Peizer 

    Acuitas Group Holdings, LLC

    Acuitas Capital LLC

    Humanitario Capital LLC 

    200 Dorado Beach Drive #3831

    Dorado, Puerto Rico 00646

      310-444-4321   

    (Name, Address and Telephone Number of Person Authorized
    to Receive Notices and Communications)

     

      June 21, 2024  
      (Date of Event which Requires Filing of this Statement)  

     

    If the filing person has previously filed a Statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D and is filing this Schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box. ¨

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 240.13d-7(b) for other parties to whom copies are to be sent.

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

    SCHEDULE 13D

     

    CUSIP No.  44919F 104   Page 2 of 11 Pages

     

    1

    NAME OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Acuitas Group Holdings, LLC

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    SOURCE OF FUNDS (See Instructions)

    OO

    5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO
    ITEMS 2(d) or 2(e)
    ¨
    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

    California

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    7

    SOLE VOTING POWER

    0

    8

    SHARED VOTING POWER

    207,923,068

    9

    SOLE DISPOSITIVE POWER

    0

    10

    SHARED DISPOSITIVE POWER

    207,923,068

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    207,923,068

    12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
    (See Instructions)
    ¨
    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

    81.89%1

    14

    TYPE OF REPORTING PERSON (See Instructions)

    OO

     

     

    1 Based on 253,908,442 deemed outstanding pursuant to Rule 13d-3(d)(1), calculated as the sum of: (i) 47,967,363 Shares issued and outstanding as of May 8, 2024, as disclosed in the Form 10-Q filed by the Company with the SEC on May 15, 2024 (the “FY24Q1 10-Q”); (ii) an aggregate of 66,075,224 Shares underlying the New Keep Well Warrants issued to Acuitas (after giving effect to the adjustment to the exercise price thereof to $0.3442 per share); (iii) 16,666,667 Shares issuable upon the conversion of the Surviving Note (after giving effect to the conversion price modification upon the effectiveness of the Stockholder Approval; assuming (1) a conversion price equal to $0.12 per share and (2) any accrued interest thereon is paid in cash); (iv) an aggregate of 37,500,000 Shares issuable upon the conversion of the Demand Notes outstanding under the Sixth Amendment (assuming, in each case, (1) a conversion price equal to $0.12 per share and (2) any accrued interest thereon is paid in cash); (v) an aggregate of 31,532,521 Shares underlying the Demand Warrants issued in connection with the purchase of the outstanding Demand Notes; and (vi) an aggregate of 54,166,667 Shares underlying the Conversion Warrants issuable upon the conversion of the Surviving Note and the outstanding Demand Notes (assuming, in each case, (1) a conversion price equal to $0.12 per share and (2) any accrued interest thereon is paid in cash), in each case, as described further in Item 5 below.

     

     

     

     

    SCHEDULE 13D

     

    CUSIP No.  44919F 104   Page 3 of 11 Pages

     

    1

    NAME OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Acuitas Capital LLC

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    SOURCE OF FUNDS (See Instructions)

    OO

    5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO
    ITEMS 2(d) or 2(e)
    ¨
    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    7

    SOLE VOTING POWER

    0

    8

    SHARED VOTING POWER

    108,333,334

    9

    SOLE DISPOSITIVE POWER

    0

    10

    SHARED DISPOSITIVE POWER

    108,333,334

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    108,333,334

    12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
    (See Instructions)
    ¨
    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

    69.31%2

    14

    TYPE OF REPORTING PERSON (See Instructions)

    OO

     

     

    2 Based on 156,300,697 Shares deemed outstanding pursuant to Rule 13d-3(d)(1), calculated as the sum of: (i) 47,967,363 Shares issued and outstanding as of May 8, 2024, as disclosed in the FY24Q1 10-Q; (ii) 16,666,667 Shares issuable upon the conversion of the Surviving Note (after giving effect to the conversion price modification upon the effectiveness of the Stockholder Approval; assuming (1) a conversion price equal to $0.12 per share and (2) any accrued interest thereon is paid in cash); (iii) an aggregate of 37,500,000 Shares issuable upon the conversion of the Demand Notes outstanding under the Sixth Amendment (assuming, in each case, (1) a conversion price equal to $0.12 per share and (2) any accrued interest thereon is paid in cash); and (iv) an aggregate of 54,166,667 Shares underlying the Conversion Warrants issuable upon the conversion of the Surviving Note and the outstanding Demand Notes (assuming, in each case, (1) a conversion price equal to $0.12 per share and (2) any accrued interest thereon is paid in cash), in each case, as described further in Item 5 below.

     

     

     

     

    SCHEDULE 13D

     

    CUSIP No.  44919F 104   Page 4 of 11 Pages

     

    1

    NAME OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Humanitario Capital LLC

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    SOURCE OF FUNDS (See Instructions)

    OO

    5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO
    ITEMS 2(d) or 2(e)
    ¨
    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Puerto Rico

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    7

    SOLE VOTING POWER

    0

    8

    SHARED VOTING POWER

    135,963,648

    9

    SOLE DISPOSITIVE POWER

    0

    10

    SHARED DISPOSITIVE POWER

    135,963,648

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    135,963,648

    12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
    (See Instructions)
    ¨
    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

    86.68%3

    14

    TYPE OF REPORTING PERSON (See Instructions)

    OO

     

     

    3 Based on 156,848,825 Shares deemed outstanding pursuant to Rule 13d-3(d)(1), calculated as the sum of: (i) 47,967,363 Shares issued and outstanding as of May 8, 2024, as disclosed in the FY24Q1 10-Q; and (ii) an aggregate of 108,881,462 Shares underlying the Private Placement Securities issued to Humanitario in November 2023, as described further in Item 5 below.

     

     

     

     

    SCHEDULE 13D

     

    CUSIP No.  44919F 104   Page 5 of 11 Pages

     

    1

    NAME OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Terren S. Peizer

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    SOURCE OF FUNDS (See Instructions)

    OO

    5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO
    ITEMS 2(d) or 2(e)
    x
    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States of America

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    7

    SOLE VOTING POWER

    343,886,716

    8

    SHARED VOTING POWER

    0

    9

    SOLE DISPOSITIVE POWER

    343,886,716

    10

    SHARED DISPOSITIVE POWER

    0

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    343,886,716

    12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
    (See Instructions)
    ¨
    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

    94.79%4

    14

    TYPE OF REPORTING PERSON (See Instructions)

    HC; IN

     

     

    4 Based on 362,789,904 Shares deemed outstanding pursuant to Rule 13d-3(d)(1), calculated as the sum of: (i) 47,967,363 Shares issued and outstanding as of May 8, 2024, as disclosed in the FY24Q1 10-Q; (ii) an aggregate of 66,075,224 Shares underlying the New Keep Well Warrants issued to Acuitas (after giving effect to the adjustment to the exercise price thereof to $0.3442 per share); (iii) an aggregate of 108,881,462 Shares underlying the Private Placement Securities issued to Humanitario in November 2023; (iv) 16,666,667 Shares issuable upon the conversion of the Surviving Note (after giving effect to the conversion price modification upon the effectiveness of the Stockholder Approval; assuming (1) a conversion price equal to $0.12 per share and (2) any accrued interest thereon is paid in cash); (v) an aggregate of 37,500,000 Shares issuable upon the conversion of the Demand Notes outstanding under the Sixth Amendment (assuming, in each case, (1) a conversion price equal to $0.12 per share and (2) any accrued interest thereon is paid in cash); (vi) an aggregate of 31,532,521 Shares underlying the Demand Warrants issued in connection with the purchase of the outstanding Demand Notes; and (vii) an aggregate of 54,166,667 Shares underlying the Conversion Warrants issuable upon the conversion of the Surviving Note and the outstanding Demand Notes (assuming, in each case, (1) a conversion price equal to $0.12 per share and (2) any accrued interest thereon is paid in cash), in each case, as described further in Item 5 below.

     

     

     

     

    SCHEDULE 13D

     

    CUSIP No.  44919F 104   Page 6 of 11 Pages

     

    AMENDMENT NO. 25 TO SCHEDULE 13D

     

    This Amendment No. 25 to Schedule 13D (this “Amendment”) is being filed by Acuitas Group Holdings, LLC, a California limited liability company (“Acuitas”), Acuitas Capital LLC, a Delaware limited liability company and a wholly owned subsidiary of Acuitas (“Acuitas Capital”), Humanitario Capital LLC, a Puerto Rico limited liability company (“Humanitario”), and Terren S. Peizer (“Mr. Peizer”) (collectively, the “Reporting Persons”) to amend the Schedule 13D originally filed with the Securities and Exchange Commission (the “SEC”) on October 20, 2010, as amended by Amendment No. 1 to Schedule 13D filed on December 6, 2011, Amendment No. 2 to Schedule 13D filed on April 27, 2012, Amendment No. 3 to Schedule 13D filed on September 20, 2012, Amendment No. 4 to Schedule 13D filed on February 14, 2013, Amendment No. 5 to Schedule 13D filed on May 11, 2021, Amendment No. 6 to Schedule 13D filed on July 27, 2021, Amendment No. 7 to Schedule 13D filed on August 16, 2021, Amendment No. 8 to Schedule 13D filed on November 2, 2021, Amendment No. 9 to Schedule 13D filed on April 18, 2022, Amendment No. 10 to Schedule 13D filed on September 2, 2022, Amendment No. 11 to Schedule 13D filed on September 8, 2022, Amendment No. 12 to Schedule 13D filed on November 22, 2022, Amendment No. 13 to Schedule 13D filed on January 4, 2023, Amendment No. 14 to Schedule 13D filed on January 6, 2023, Amendment No. 15 to Schedule 13D filed on February 23, 2023, Amendment No. 16 to Schedule 13D filed on March 7, 2023, Amendment No. 17 to Schedule 13D filed on March 8, 2023, Amendment No. 18 to Schedule 13D filed on June 27, 2023, Amendment No. 19 to Schedule 13D filed on November 2, 2023, Amendment No. 20 to Schedule 13D filed on November 15, 2023, Amendment No. 21 to Schedule 13D filed on December 20, 2023, Amendment No. 22 to Schedule 13D filed on April 1, 2024, Amendment No. 23 to Schedule 13D filed on April 10, 2024 and Amendment No. 24 to Schedule 13D filed on June 5, 2024 (as amended and supplemented, the “Original Statement” and, as amended and supplemented by this Amendment, the “Statement”), relating to common stock, par value $0.0001 per share (the “Shares”), of Ontrak, Inc., a Delaware corporation (the “Company”). Capitalized terms used herein but not defined have the respective meanings ascribed to them in the Original Statement.

     

      ITEM 2. Identity and Background

     

    Item 2 of the Statement is hereby amended and supplemented by adding the following:

     

    “On June 21, 2024, Mr. Peizer was found guilty by a jury in the Central District of California of one count of securities fraud and two counts of insider trading. The allegations related to the sale of shares of the Company through the use of two Rule 10b5-1 trading plans. Mr. Peizer’s conviction is not yet final, and he plans to appeal the verdict.

     

    Other than as set forth above, during the last five years, no Reporting Person has been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) and no Reporting Person has been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction as a result of which such Reporting Person was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.”

     

      ITEM 5. INTEREST IN SECURITIES OF THE ISSUER

     

    Item 5(a) and (b) of the Statement is amended and restated in its entirety as follows:

     

    “(a) and (b)

     

    Acuitas

     

    All percentages of Shares outstanding contained herein with respect to Acuitas are based on 253,908,442 Shares deemed outstanding pursuant to Rule 13d-3(d)(1), calculated as the sum of:

     

      (i) 47,967,363 Shares issued and outstanding as of May 8, 2024, as disclosed by the Company in the Quarterly Report on Form 10-Q filed with the SEC on May 15, 2024 (the “FY2024 Q1 10-Q”);
         
      (ii) an aggregate of 66,075,224 Shares underlying the New Keep Well Warrants issued to Acuitas (after giving effect to the adjustment to the exercise price thereof to $0.3442 per share);

     

     

     

     

      (iii) 16,666,667 Shares issuable to Acuitas Capital (or its designee) upon the conversion of the Surviving Note (after giving effect to the adjustment to the conversion price upon the effectiveness of the Stockholder Approval, and assuming (1) a conversion price equal to $0.12 per share and (2) any accrued interest thereon is paid in cash);
         
      (iv) an aggregate of 37,500,000 Shares issuable to Acuitas Capital (or its designee) upon the conversion of the Initial Demand Note and the Demand Notes purchased by Acuitas Capital on May 8, 2024 and June 5, 2024 (assuming, in each case, (1) a conversion price equal to $0.12 per share and (2) any accrued interest thereon is paid in cash);
         
      (v) an aggregate of 31,532,521 Shares underlying the Demand Warrants issued to Acuitas in connection with the purchase of Demand Notes pursuant to the Sixth Amendment, representing the sum of (1) 8,715,863 Shares underlying the Demand Warrant issued in connection with the Initial Demand Note (assuming an initial exercise price of $0.3442 per share), (2) 11,278,196 Shares underlying the Demand Warrant issued in respect of the Demand Note purchased on May 8, 2024 (assuming an initial exercise price of $0.266 per share), and (3) 11,538,462 Shares underlying the Demand Warrant issued in respect of the Demand Note purchased on June 5, 2024 (assuming an initial exercise price of $0.26 per share); and
         
      (vi) an aggregate of 54,166,667 Shares underlying the Conversion Warrants issuable to Acuitas Capital (or its designee), representing the sum of (1) 16,666,667 Shares underlying the Conversion Warrant issuable upon the conversion of the Surviving Note (assuming (I) a conversion price equal to $0.12 per share and (II) any accrued interest thereon is paid in cash) and (2) an aggregate of 37,500,000 Shares underlying the Conversion Warrants issuable upon the conversion of the Initial Demand Note and the Demand Notes purchased by Acuitas Capital on May 8, 2024 and June 5, 2024 (assuming, in each case, (I) a conversion price equal to $0.12 per share and (II) any accrued interest thereon is paid in cash).

     

    As of June 25, 2024, Acuitas may be deemed to have beneficial ownership of 207,923,068 Shares, consisting of:

      

      (i) an aggregate of 1,981,989 Shares owned by Acuitas as of the date hereof;
         
      (ii) an aggregate of 66,075,224 Shares underlying the New Keep Well Warrants issued to Acuitas (after giving effect to the adjustment to the exercise price thereof to $0.3442 per share);
         
      (iii) 16,666,667 Shares issuable to Acuitas Capital (or its designee) upon the conversion of the Surviving Note (after giving effect to the adjustment to the conversion price upon the effectiveness of the Stockholder Approval, and assuming (1) a conversion price equal to $0.12 per share and (2) any accrued interest thereon is paid in cash);
         
      (iv) an aggregate of 37,500,000 Shares issuable to Acuitas Capital (or its designee) upon the conversion of the Initial Demand Note and the Demand Notes purchased by Acuitas Capital on May 8, 2024 and June 5, 2024 (assuming, in each case, (1) a conversion price equal to $0.12 per share and (2) any accrued interest thereon is paid in cash);
         
      (v) an aggregate of 31,532,521 Shares underlying the Demand Warrants issued to Acuitas in connection with the purchase of Demand Notes pursuant to the Sixth Amendment, representing the sum of (1) 8,715,863 Shares underlying the Demand Warrant issued in connection with the Initial Demand Note (assuming an initial exercise price of $0.3442 per share), (2) 11,278,196 Shares underlying the Demand Warrant issued in respect of the Demand Note purchased on May 8, 2024 (assuming an initial exercise price of $0.266 per share), and (3) 11,538,462 Shares underlying the Demand Warrant issued in respect of the Demand Note purchased on June 5, 2024 (assuming an initial exercise price of $0.26 per share); and
         
      (vi) an aggregate of 54,166,667 Shares underlying the Conversion Warrants issuable to Acuitas Capital (or its designee), representing the sum of (1) 16,666,667 Shares underlying the Conversion Warrant issuable upon the conversion of the Surviving Note (assuming (I) a conversion price equal to $0.12 per share and (II) any accrued interest thereon is paid in cash) and (2) an aggregate of 37,500,000 Shares underlying the Conversion Warrants issuable upon the conversion of the Initial Demand Note and the Demand Notes purchased by Acuitas Capital on May 8, 2024 and June 5, 2024 (assuming, in each case, (I) a conversion price equal to $0.12 per share and (II) any accrued interest thereon is paid in cash).

     

     

     

     

    The Shares beneficially owned by Acuitas represents approximately 81.89% of the total number of Shares outstanding as of June 25, 2024. Acuitas may be deemed to share the power to vote or direct the vote and dispose or direct the disposition of 207,923,068 Shares with Mr. Peizer. Acuitas may be deemed to share the power to vote or direct the vote and dispose or direct the disposition of 108,333,334 Shares with Acuitas Capital and Mr. Peizer.

     

    Acuitas Capital

     

    All percentages of Shares outstanding contained herein with respect to Acuitas Capital are based on 156,300,697 Shares deemed outstanding pursuant to Rule 13d-3(d)(1), calculated as the sum of:

     

      (i) 47,967,363 Shares issued and outstanding as of May 8, 2024, as disclosed in the FY2024 Q1 10-Q;
         
      (ii) 16,666,667 Shares issuable to Acuitas Capital (or its designee) upon the conversion of the Surviving Note (after giving effect to the adjustment to the conversion price upon the effectiveness of the Stockholder Approval, and assuming (1) a conversion price equal to $0.12 per share and (2) any accrued interest thereon is paid in cash);
         
      (iii) an aggregate of 37,500,000 Shares issuable to Acuitas Capital (or its designee) upon the conversion of the Initial Demand Note and the Demand Notes purchased by Acuitas Capital on May 8, 2024 and June 5, 2024 (assuming, in each case, (1) a conversion price equal to $0.12 per share and (2) any accrued interest thereon is paid in cash); and
         
      (iv) an aggregate of 54,166,667 Shares underlying the Conversion Warrants issuable to Acuitas Capital (or its designee), representing the sum of (1) 16,666,667 Shares underlying the Conversion Warrant issuable upon the conversion of the Surviving Note (assuming (I) a conversion price equal to $0.12 per share and (II) any accrued interest thereon is paid in cash) and (2) an aggregate of 37,500,000 Shares underlying the Conversion Warrants issuable upon the conversion of the Initial Demand Note and the Demand Notes purchased by Acuitas Capital on May 8, 2024 and June 5, 2024 (assuming, in each case, (I) a conversion price equal to $0.12 per share and (II) any accrued interest thereon is paid in cash).

     

    As of June 25, 2024, Acuitas Capital may be deemed to have beneficial ownership of 108,333,334 Shares, consisting of:

     

      (i) 16,666,667 Shares issuable to Acuitas Capital (or its designee) upon the conversion of the Surviving Note (after giving effect to the adjustment to the conversion price upon the effectiveness of the Stockholder Approval, and assuming (1) a conversion price equal to $0.12 per share and (2) any accrued interest thereon is paid in cash);
         
      (ii) an aggregate of 37,500,000 Shares issuable to Acuitas Capital (or its designee) upon the conversion of the Initial Demand Note and the Demand Notes purchased by Acuitas Capital on May 8, 2024 and June 5, 2024 (assuming, in each case, (1) a conversion price equal to $0.12 per share and (2) any accrued interest thereon is paid in cash); and
         
      (iii) An aggregate of 54,166,667 Shares underlying the Conversion Warrants issuable to Acuitas Capital (or its designee), representing the sum of (1) 16,666,667 Shares underlying the Conversion Warrant issuable upon the conversion of the Surviving Note (assuming (I) a conversion price equal to $0.12 per share and (II) any accrued interest thereon is paid in cash) and (2) an aggregate of 37,500,000 Shares underlying the Conversion Warrants issuable upon the conversion of the Initial Demand Note and the Demand Notes purchased by Acuitas Capital on May 8, 2024 and June 5, 2024 (assuming, in each case, (I) a conversion price equal to $0.12 per share and (II) any accrued interest thereon is paid in cash).
         

    The Shares beneficially owned by Acuitas Capital represents approximately 69.31% of the total number of Shares outstanding as of June 25, 2024. Acuitas Capital may be deemed to share the power to vote or direct the vote and dispose or direct the disposition of all of the 108,333,334 Shares with Acuitas and Mr. Peizer.

     

     

     

     

    Humanitario

     

    All percentages of Shares outstanding contained herein with respect to Humanitario are based on 156,848,825 Shares deemed outstanding pursuant to Rule 13d-3(d)(1), calculated as the sum of:

     

      (i) 47,967,363 Shares issued and outstanding as of May 8, 2024, as disclosed in the FY2024 Q1 10-Q; and
         
      (ii) an aggregate of 108,881,462 Shares underlying the Private Placement Securities (as previously defined in the Original Statement) issued to Humanitario in November 2023, representing the sum of (1) 18,333,333 Shares underlying the Private Placement Pre-Funded Warrant (as previously defined in the Original Statement) and (2) 90,548,129 Shares underlying the Private Placement Warrant (as previously defined in the Original Statement).

     

    As of June 25, 2024, Humanitario may be deemed to have beneficial ownership of 135,963,648 Shares, consisting of:

     

      (i) an aggregate of 27,082,186 Shares owned by Humanitario as of the date hereof; and
         
      (ii) an aggregate of 108,881,462 Shares underlying the Private Placement Securities issued to Humanitario in November 2023, representing the sum of (1) 18,333,333 Shares underlying the Private Placement Pre-Funded Warrant and (2) 90,548,129 Shares underlying the Private Placement Warrant.
         

    The Shares beneficially owned by Humanitario represents approximately 86.68% of the total number of Shares outstanding as of June 25, 2024. Humanitario may be deemed to share the power to vote or direct the vote and dispose or direct the disposition of all of the 135,963,648 Shares with Mr. Peizer.

     

    Mr. Peizer

     

    All percentages of Shares outstanding contained herein with respect to Mr. Peizer are based on 362,789,904 Shares deemed outstanding pursuant to Rule 13d-3(d)(1), calculated as the sum of:

     

      (i) 47,967,363 Shares issued and outstanding as of May 8, 2024, as disclosed in the FY2024 Q1 10-Q;
         
      (ii) an aggregate of 66,075,224 Shares underlying the New Keep Well Warrants issued to Acuitas (after giving effect to the adjustment to the exercise price thereof to $0.3442 per share);
         
      (iii) an aggregate of 108,881,462 Shares underlying the Private Placement Securities issued to Humanitario in November 2023, representing the sum of (1) 18,333,333 Shares underlying the Private Placement Pre-Funded Warrant and (2) 90,548,129 Shares underlying the Private Placement Warrant.
         
      (iv) 16,666,667 Shares issuable to Acuitas Capital (or its designee) upon the conversion of the Surviving Note (after giving effect to the adjustment to the conversion price upon the effectiveness of the Stockholder Approval, and assuming (1) a conversion price equal to $0.12 per share and (2) any accrued interest thereon is paid in cash);
         
      (v) an aggregate of 37,500,000 Shares issuable to Acuitas Capital (or its designee) upon the conversion of the Initial Demand Note and the Demand Notes purchased by Acuitas Capital on May 8, 2024 and June 5, 2024 (assuming, in each case, (1) a conversion price equal to $0.12 per share and (2) any accrued interest thereon is paid in cash);
         
      (vi) an aggregate of 31,532,521 Shares underlying the Demand Warrants issued to Acuitas in connection with the purchase of Demand Notes pursuant to the Sixth Amendment, representing the sum of (1) 8,715,863 Shares underlying the Demand Warrant issued in connection with the Initial Demand Note (assuming an initial exercise price of $0.3442 per share), (2) 11,278,196 Shares underlying the Demand Warrant issued in respect of the Demand Note purchased on May 8, 2024 (assuming an initial exercise price of $0.266 per share), and (3) 11,538,462 Shares underlying the Demand Warrant issued in respect of the Demand Note purchased on June 5, 2024 (assuming an initial exercise price of $0.26 per share); and
         
      (vii) an aggregate of 54,166,667 Shares underlying the Conversion Warrants issuable to Acuitas Capital (or its designee), representing the sum of (1) 16,666,667 Shares underlying the Conversion Warrant issuable upon the conversion of the Surviving Note (assuming (I) a conversion price equal to $0.12 per share and (II) any accrued interest thereon is paid in cash) and (2) an aggregate of 37,500,000 Shares underlying the Conversion Warrants issuable upon the conversion of the Initial Demand Note and the Demand Notes purchased by Acuitas Capital on May 8, 2024 and June 5, 2024 (assuming, in each case, (I) a conversion price equal to $0.12 per share and (II) any accrued interest thereon is paid in cash).

     

     

     

     

    As of June 25, 2024, Mr. Peizer may be deemed to have beneficial ownership of 343,886,716 Shares, consisting of:

     

      (i) an aggregate of 29,064,175 Shares beneficially owned by Mr. Peizer as of the date hereof, representing the sum of (1) 1,981,989 Shares owned by Acuitas as of the date hereof and (2) 27,082,186 Shares owned by Humanitario as of the date hereof;
         
      (ii) an aggregate of 66,075,224 Shares underlying the New Keep Well Warrants issued to Acuitas (after giving effect to the adjustment to the exercise price thereof to $0.3442 per share);
         
      (iii) an aggregate of 108,881,462 Shares underlying the Private Placement Securities issued to Humanitario in November 2023, representing the sum of (1) 18,333,333 Shares underlying the Private Placement Pre-Funded Warrant and (2) 90,548,129 Shares underlying the Private Placement Warrant;
         
      (iv) 16,666,667 Shares issuable to Acuitas Capital (or its designee) upon the conversion of the Surviving Note (after giving effect to the adjustment to the conversion price upon the effectiveness of the Stockholder Approval, and assuming (1) a conversion price equal to $0.12 per share and (2) any accrued interest thereon is paid in cash);
         
      (v) an aggregate of 37,500,000 Shares issuable to Acuitas Capital (or its designee) upon the conversion of the Initial Demand Note and the Demand Notes purchased by Acuitas Capital on May 8, 2024 and June 5, 2024 (assuming, in each case, (1) a conversion price equal to $0.12 per share and (2) any accrued interest thereon is paid in cash);
         
      (vi) an aggregate of 31,532,521 Shares underlying the Demand Warrants issued to Acuitas in connection with the purchase of Demand Notes pursuant to the Sixth Amendment, representing the sum of (1) 8,715,863 Shares underlying the Demand Warrant issued in connection with the Initial Demand Note (assuming an initial exercise price of $0.3442 per share), (2) 11,278,196 Shares underlying the Demand Warrant issued in respect of the Demand Note purchased on May 8, 2024 (assuming an initial exercise price of $0.266 per share), and (2) 11,538,462 Shares underlying the Demand Warrant issued in respect of the Demand Note purchased on June 5, 2024 (assuming an initial exercise price of $0.26 per share); and
         
      (vii) an aggregate of 54,166,667 Shares underlying the Conversion Warrants issuable to Acuitas Capital (or its designee), representing the sum of (1) 16,666,667 Shares underlying the Conversion Warrant issuable upon the conversion of the Surviving Note (assuming (I) a conversion price equal to $0.12 per share and (II) any accrued interest thereon is paid in cash) and (2) an aggregate of 37,500,000 Shares underlying the Conversion Warrants issuable upon the conversion of the Initial Demand Note and the Demand Notes purchased by Acuitas Capital on May 8, 2024 and June 5, 2024 (assuming, in each case, (I) a conversion price equal to $0.12 per share and (II) any accrued interest thereon is paid in cash).

      

    The Shares beneficially owned by Mr. Peizer represents approximately 94.79% of the total number of Shares outstanding as of June 25, 2024. Mr. Peizer may be deemed to have the sole power to vote or direct the vote and dispose or direct the disposition of all of the 343,886,716 Shares.”

     

     Item 5(c) of the Statement is hereby supplemented with the following:

     

    “The Reporting Persons had no transactions in the securities of the Company since the most recent filing on Schedule 13D.”

     

     

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated:  June 25, 2024

     

      ACUITAS GROUP HOLDINGS, LLC
       
      By: /s/ Terren S. Peizer
        Terren S. Peizer, Chairman
       
      ACUITAS CAPITAL LLC
       
      By: /s/ Terren S. Peizer
        Terren S. Peizer, Chairman
       
      HUMANITARIO CAPITAL LLC
       
      By: /s/ Terren S. Peizer
        Terren S. Peizer, Sole Member
       
      /s/ Terren S. Peizer
      Terren S. Peizer

     

     

    Get the next $OTRK alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $OTRK

    DatePrice TargetRatingAnalyst
    12/5/2023$4.00Buy
    ROTH MKM
    3/9/2022$13.00 → $2.50Hold
    Canaccord Genuity
    3/9/2022$11.00 → $2.00Sector Perform
    RBC Capital
    8/20/2021$35.00 → $9.00Market Perform → Underperform
    Cowen & Co.
    8/20/2021$15.00Buy → Neutral
    B. Riley Securities
    More analyst ratings

    $OTRK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Large owner Peizer Terren S

      4 - Ontrak, Inc. (0001136174) (Issuer)

      5/20/25 5:31:02 PM ET
      $OTRK
      Misc Health and Biotechnology Services
      Health Care
    • SEC Form 4 filed by Large owner Peizer Terren S

      4 - Ontrak, Inc. (0001136174) (Issuer)

      4/1/25 9:24:56 PM ET
      $OTRK
      Misc Health and Biotechnology Services
      Health Care
    • SEC Form 4 filed by Director Sherman Michael Edward

      4 - Ontrak, Inc. (0001136174) (Issuer)

      1/6/25 8:08:28 PM ET
      $OTRK
      Misc Health and Biotechnology Services
      Health Care

    $OTRK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • ROTH MKM initiated coverage on Ontrak with a new price target

      ROTH MKM initiated coverage of Ontrak with a rating of Buy and set a new price target of $4.00

      12/5/23 8:03:01 AM ET
      $OTRK
      Misc Health and Biotechnology Services
      Health Care
    • Canaccord Genuity reiterated coverage on Ontrak with a new price target

      Canaccord Genuity reiterated coverage of Ontrak with a rating of Hold and set a new price target of $2.50 from $13.00 previously

      3/9/22 9:09:19 AM ET
      $OTRK
      Misc Health and Biotechnology Services
      Health Care
    • RBC Capital reiterated coverage on Ontrak with a new price target

      RBC Capital reiterated coverage of Ontrak with a rating of Sector Perform and set a new price target of $2.00 from $11.00 previously

      3/9/22 7:43:55 AM ET
      $OTRK
      Misc Health and Biotechnology Services
      Health Care

    $OTRK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Ontrak Inc.

      SC 13G/A - Ontrak, Inc. (0001136174) (Subject)

      11/14/24 4:24:03 PM ET
      $OTRK
      Misc Health and Biotechnology Services
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Ontrak Inc.

      SC 13D/A - Ontrak, Inc. (0001136174) (Subject)

      10/3/24 6:37:08 PM ET
      $OTRK
      Misc Health and Biotechnology Services
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Ontrak Inc.

      SC 13D/A - Ontrak, Inc. (0001136174) (Subject)

      8/30/24 5:15:15 PM ET
      $OTRK
      Misc Health and Biotechnology Services
      Health Care

    $OTRK
    Financials

    Live finance-specific insights

    See more
    • Ontrak Health Announces 2025 First Quarter Financial Results

      Q1 Revenue of $2.0 million, down 25% year over year Q1 Operating loss of $(5.9) million, a 37% increase year over year Q1 Adjusted EBITDA of $(4.3) million, a 28% decline year over year Company announces securing a $10.0 million financing commitment from Acuitas Capital LLC Company announces recertification by the National Committee for Quality Assurance (NCQA) as a Credentials Verification Organization (CVO) Company to Host Conference Call at 4:30 pm ET Today Ontrak, Inc. (NASDAQ:OTRK) ("Ontrak" or the "Company"), a leading AI-powered and technology-enabled behavioral healthcare company, today reported its financial results for the first quarter ended March 31, 2025. Manageme

      5/20/25 4:05:00 PM ET
      $OTRK
      Misc Health and Biotechnology Services
      Health Care
    • Ontrak Health to Report 2025 First Quarter Financial Results on May 20, 2025

      Ontrak Health (NASDAQ:OTRK) ("Ontrak" or the "Company"), a leading AI-powered and telehealth-enabled healthcare company, today announced it will report financial results for the first quarter 2025 on Tuesday, May 20, 2025, after market close. Company management will host a corresponding conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Conference Call & Webcast Details The conference call can be accessed by registering online for dial-in information or via live audio webcast at: https://ontrakhealth.com/investors/presentations-events . Participants interested in dialing in to the conference call are requested to register a day in advance or at a minimum 15 minutes before

      5/19/25 4:30:00 PM ET
      $OTRK
      Misc Health and Biotechnology Services
      Health Care
    • Ontrak Health to Report 2024 Fourth Quarter Financial Results on April 14, 2025

      Ontrak Health (NASDAQ:OTRK) ("Ontrak" or the "Company"), a leading AI-powered and telehealth-enabled healthcare company, today announced it will report financial results for the fourth quarter 2024 on Monday, April 14, 2025, after market close. Company management will host a corresponding conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Conference Call & Webcast Details The conference call can be accessed by registering online for dial-in information or via live audio webcast at: https://ontrakhealth.com/delivering-a-healthier-future-for-all/presentations-events/. Participants interested in dialing in to the conference call are requested to register a day in advance or

      4/10/25 4:05:00 PM ET
      $OTRK
      Misc Health and Biotechnology Services
      Health Care

    $OTRK
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Ontrak Health Announces 2025 First Quarter Financial Results

      Q1 Revenue of $2.0 million, down 25% year over year Q1 Operating loss of $(5.9) million, a 37% increase year over year Q1 Adjusted EBITDA of $(4.3) million, a 28% decline year over year Company announces securing a $10.0 million financing commitment from Acuitas Capital LLC Company announces recertification by the National Committee for Quality Assurance (NCQA) as a Credentials Verification Organization (CVO) Company to Host Conference Call at 4:30 pm ET Today Ontrak, Inc. (NASDAQ:OTRK) ("Ontrak" or the "Company"), a leading AI-powered and technology-enabled behavioral healthcare company, today reported its financial results for the first quarter ended March 31, 2025. Manageme

      5/20/25 4:05:00 PM ET
      $OTRK
      Misc Health and Biotechnology Services
      Health Care
    • Ontrak Secures Financing Commitment to Fuel Growth and Innovation

      Ontrak, Inc. (NASDAQ:OTRK), a leading value-based behavioral healthcare company powered by proprietary AI and engagement technology, announced it has secured a $10 million financing commitment from Acuitas Capital, LLC. This financing commitment will support Ontrak's continued growth and innovation in delivering comprehensive behavioral healthcare solutions and is structured to provide Ontrak with the necessary capital to expand its customer base while continuing to drive further advancements in its AI and digital capabilities. The commitment contemplates that Ontrak may raise additional financing from third parties to further support its growth initiatives. Brandon LaVerne, Chief Executiv

      5/20/25 8:00:00 AM ET
      $OTRK
      Misc Health and Biotechnology Services
      Health Care
    • Ontrak Health to Report 2025 First Quarter Financial Results on May 20, 2025

      Ontrak Health (NASDAQ:OTRK) ("Ontrak" or the "Company"), a leading AI-powered and telehealth-enabled healthcare company, today announced it will report financial results for the first quarter 2025 on Tuesday, May 20, 2025, after market close. Company management will host a corresponding conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Conference Call & Webcast Details The conference call can be accessed by registering online for dial-in information or via live audio webcast at: https://ontrakhealth.com/investors/presentations-events . Participants interested in dialing in to the conference call are requested to register a day in advance or at a minimum 15 minutes before

      5/19/25 4:30:00 PM ET
      $OTRK
      Misc Health and Biotechnology Services
      Health Care

    $OTRK
    SEC Filings

    See more
    • SEC Form 10-Q filed by Ontrak Inc.

      10-Q - Ontrak, Inc. (0001136174) (Filer)

      5/20/25 4:08:00 PM ET
      $OTRK
      Misc Health and Biotechnology Services
      Health Care
    • Ontrak Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Ontrak, Inc. (0001136174) (Filer)

      5/20/25 4:05:48 PM ET
      $OTRK
      Misc Health and Biotechnology Services
      Health Care
    • Ontrak Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

      8-K - Ontrak, Inc. (0001136174) (Filer)

      5/20/25 8:02:18 AM ET
      $OTRK
      Misc Health and Biotechnology Services
      Health Care

    $OTRK
    Leadership Updates

    Live Leadership Updates

    See more
    • Ontrak Names James Messina to its Board of Directors

      Ontrak, Inc. (NASDAQ:OTRK) ("Ontrak" or the "Company"), a leading AI-powered and telehealth-enabled healthcare company, today announced the appointment of James Messina as a non-Executive Director to its board. Mr. Messina is a Co-Founder and General Partner of Seattle Hill Ventures and x4 Capital Partners, which invest in, and support, startup ventures by providing business development, marketing, operating and technology support. Previously, Mr. Messina was the Executive Vice President and Chief Operating Officer for Premera Blue Cross ("Premera"). He was responsible for effectively servicing the needs of Premera's customers with oversight of all operational functions, from customer serv

      8/30/22 8:00:00 AM ET
      $OTRK
      Misc Health and Biotechnology Services
      Health Care
    • Ontrak Names Dr. Robert Accordino Chief Medical Officer

      Mental Healthcare Leader and Harvard Medical School Faculty Member Joins Ontrak Ontrak, Inc (NASDAQ:OTRK) ("Ontrak" or the "Company"), a leading AI-powered and telehealth-enabled healthcare company, today announced the appointment of Dr. Robert Accordino as Ontrak's Chief Medical Officer, effective September 27, 2021. Dr. Accordino joins Ontrak from Quartet Health where he served as the company's most senior clinician and Chief Mental Health Officer. He practices psychiatry and is on the faculty of Harvard Medical School and Massachusetts General Hospital. Dr. Accordino will report to Jonathan Mayhew, CEO, who joined Ontrak from CVS Health earlier this year. "Dr. Accordino's reputation in

      9/9/21 8:00:00 AM ET
      $OTRK
      Misc Health and Biotechnology Services
      Health Care
    • Arik Hill Joins Ontrak as Chief Information Officer

      Former Accenture and KPMG Healthcare Expert Brings Proven Leadership Experience In Behavioral Health Digital Transformation Ontrak, Inc (NASDAQ:OTRK) ("Ontrak" or the "Company"), a leading AI-powered and telehealth-enabled healthcare company, today announced the appointment of Arik Hill as Ontrak's first Chief Information Officer, effective August 30, 2021. Mr. Hill will report to Jonathan Mayhew, CEO, who joined Ontrak from CVS Health earlier this year. "As Chief Information Officer at The New York Foundling, a fast growing organization that collaborates with over 250,000 behavioral healthcare partners across the country, Arik led the development of digital platforms and applications th

      8/12/21 8:00:00 AM ET
      $OTRK
      Misc Health and Biotechnology Services
      Health Care